PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
PALISADE BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.34−0.07 (-4.96%)
Close on Oct 19, 2026
- Market cap
- $283.25M
- P/E (TTM)
- –
- Dividend yield
- –
Palisade Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Market Cap | $233.52M | $166.30M |
| Enterprise Value | $108.35M | $87.12M |
| PS Ratio | 467.05 | 3.60 |
| PB Ratio | 1.92 | 2.03 |
| P/TBV Ratio | 1.92 | 2.31 |
Enterprise value
| Measure | Palisade Bio | Industry median |
|---|---|---|
| EV / Sales | 216.70 | 2.43 |
Income (trailing twelve months)
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Revenue | $500.00K | $57.94M |
| Operating Income | -$35.35M | -$21.49M |
| Net Income | -$31.94M | -$22.46M |
| EBITDA | -$35.35M | -$17.14M |
Margins
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Operating Margin | -7069.8% | -44.5% |
| Profit Margin | -6388.2% | -39.2% |
| EBITDA Margin | -7069.8% | -31.3% |
Returns
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -51.4% | -53.2% |
| Return on Assets (ROA) | -47.7% | -41.0% |
| Return on Capital Employed (ROCE) | -29.0% | -38.0% |
Balance sheet
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $125.17M | $62.64M |
| Net Cash (Debt) | $125.17M | $15.77M |
| Net Cash Per Share | $0.72 | $0.66 |
| Equity (Book Value) | $121.75M | $48.61M |
| Book Value Per Share | $0.70 | $1.36 |
| Tangible Book Value | $121.75M | $23.01M |
| Working Capital | $122.01M | $75.09M |
Financial position
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Current Ratio | 24.26 | 3.30 |
| Quick Ratio | 23.96 | 2.39 |
| Interest Coverage | -4418.63 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$18.19M | -$12.39M |
Efficiency
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $5 | $398.96K |
| Profits Per Employee | -$319 | -$705.27K |
| Employee Count | 100,000 | 74 |
Dividends and yields
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Earnings Yield | -13.7% | -22.8% |
| Buyback Yield | -56.3% | -0.73% |
| Shareholder Yield | -56.3% | 0.00% |
Shares
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Shares Outstanding | 174,271,000 | 58,139,000 |
| Shares Change (QoQ) | 3.69% | 0.54% |
| Float | 170,422,000 | 49,154,900 |
| Shares Held by Insiders | 2.21% | 11.6% |
| Shares Held by Institutions | 99.5% | 59.4% |
Scores
| Measure | Palisade Bio | Industry median |
|---|---|---|
| Altman Z-Score | 25.41 | -0.27 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Palisade Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.